Ebola research and development landscape of clinical candidates and trials
Public report October, 2015
Transparency and timely results sharing in clinical trials are extremely important to generate reliable evidence. They are even more crucial when testing is carried out in emergency settings.
A report published today presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
Commissioned by the Bill and Melinda Gates Foundation and the US Foundation for the National Institutes for Health, with support from Wellcome Trust and the WHO, the Ebola R&D landscape of clinical candidates and trials aims to contribute to greater transparency in medical research.
“This landscape is a useful contribution to the need for transparency and results sharing in clinical R&D so that science and patients can truly benefit,” says Marie-Paule Kieny, WHO Assistant Director General.